Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray

Rafael R. de Assis; Aarti Jain; Rie Nakajima; Algis Jasinskas; Jiin Felgner; Joshua M. Obiero; Oluwasanmi Adenaiye; Sheldon Tai; Filbert Hong; Philip Norris; Mars Stone; Graham Simmons; Anil Bagri; Martin Schreiber; Andreas Buser; Andreas Holbro; Manuel Battegay; Donald K. Milton; Huw Davies; Laurence M. Corash; Michael P. Busch; Philip L. Felgner; Saahir Khan

The coronavirus antigen microarray is intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. (Irvine, CA), a private company for which Philip L. Felgner is the largest shareholder and several co-authors (de Assis, Jain, Nakajima, Jasinskas, Obiero, Davies, and Khan) also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. (Beijing, China) which expressed and purified the antigens used in this study. The convalescent plasma used in this study was collected for clinical use by independent blood centers using licensed plasma or platelet processing systems manufactured by Cerus Corporation, for which multiple authors (Corash, Bagri) are shareholders and employees. Manuel Battegay, Andreas Buser and Andreas Holbro are employees of the University of Basel and have no conflicts of interest. Figure 1 . Heatmap for coronavirus antigen microarray. The heatmap shows IgG (A) and IgA (B) reactivity measured as mean fluorescence intensity across four replicates, against each antigen organized into rows color coded by virus, for sera organized into columns classified as positive (convalescent from PCR-positive individuals) or negative (prior to pandemic from naïve individuals). Reactivity is represented by color (white = low, black = mid, red = high).